Probiotics, secretory IgA and infection
View Patent ↗Ways to increase the effectiveness of probiotics is disclosed. One embodiment relates to a combination of probiotics with secretory IgA and possible uses of this combination. For example, a method of using a composition comprising secretory IgA and at least one probiotic to prepare a product to treat or prevent infection is disclosed.
1. A product comprising SIgA and a probiotic micro-organism and selected from the group consisting of a food product formulated for consumption by humans, an animal food product, and a pharmaceutical composition, the SIgA and the probiotic micro-organism are present in the form of a complex with each other, and the SIgA and the probiotic micro-organism are present in the product in a stoichiometric ratio of at least 100:1.
2. The product of claim 1 wherein the product is formulated for administration to at least one individual selected from the group consisting of a newborn, an infant, a juvenile, an adult, an elderly individual, and a mother during pregnancy or lactation.
3. The product of claim 1 comprising milk from an animal or plant source.
4. The product of claim 3 wherein the milk is selected from the group consisting of cow milk, human milk, sheep milk, goat milk, horse milk, camel milk, rice milk and soy milk.
5. The product of claim 1 comprising milk-derived protein fractions or colostrum.
6. The product of claim 1 comprising a prebiotic.
7. The product of claim 6 wherein the prebiotic is selected from the group consisting of oligosaccharides, dietary fibers, and mixtures thereof.
8. The product of claim 6 wherein the prebiotic is selected from the group consisting of fructo-oligosaccharide, galacto-oligosaccharide, manno-oligosaccharide, soluble fiber, soy fiber, inulin, and mixtures thereof.
9. The product of claim 6 wherein the prebiotic is selected from the group consisting of fructo-oligosaccharide, galacto-oligosaccharide, isomalto-oligosaccharide, xylooligosaccharide, an oligosaccharide of soy, glycosyl sucrose, lactosucrose, lactulose, palatinoseoligosaccharide, maltooligosaccharide, pectin, hydrolysates thereof, and mixtures thereof.
10. The product of claim 1 comprising between 10 2 and 10 10 cells of the probiotic micro-organism per daily dose.
11. The product of claim 1 comprising between 0.0001 mg and 10 mg of the SIgA per daily dose.
12. The product of claim 1 wherein the probiotic micro-organism is selected from Bifidobacterium, Lactobacillus, Streptococcus, Saccharomyces and mixtures thereof.
13. The product of claim 1 wherein the probiotic micro-organism is selected from the group consisting of Bifidobacterium longum, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus salivarius, Enterococcus faecium, Saccharomyces boulardii, Lactobacillus reuteri , and mixtures thereof.
14. The product of claim 1 wherein the probiotic micro-organism is selected from the group consisting of: Lactobacillus johnsonii NCC533 (CNCM I-1225), Bifidobacterium longum NCC490 (CNCM I-2170), Bifidobacterium longum NCC2705 (CNCM I-2618), Bifidobacterium lactis NCC2818 (CNCM I-3446), Lactobacillus paracasei NCC2461 (CNCM I-2116), Lactobacillus rhamnosus GG (ATCC53103), Lactobacillus rhamnosus NCC4007 (CGMCC 1.3724), Enterococcus faecium SF 68 (NCIMB10415), and mixtures thereof.